/
Other
Advanced NSCLC
63
Pipeline Programs↗
55
Active Trials↗
52
Companies Involved↗
Advanced NSCLC is a moderately active landscape with 63 programs across 52 companies. The most active players are Avistone Biotechnology Co., Ltd., HC Biopharma Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 111
Phase 244
Phase 36
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
48 of 62 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 62 classified programs, each share of the total. Modality classified for 100% of 63 pipeline programs.
Analysis
Trial Status
161
clinical trials
Unknown status49 · 30%
Completed41 · 25%
Recruiting28 · 17%
Not yet recruiting14 · 9%
Terminated13 · 8%
Active, not recruiting12 · 7%
Other4 · 2%
Clinical Trials
Trial Activity
161 trials
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT05060796·11 enrolled
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Recruiting·—·Phase 4·NCT04401059·744 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)